文献速递妇科

高危子宫内膜癌辅助放化疗对比单纯放疗:系统综述与Meta分析

Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2018-03-09

该系统综述与Meta分析纳入6项前瞻性随机对照试验共2105例高危子宫内膜癌患者,比较术后辅助放化疗与单纯放疗。放化疗显著延长5年无进展生存(80.2% vs 74.5%)和5年癌症特异性生存(86.1% vs 79.0%),但III/IV级急性毒性发生率更高,总生存、局部复发率、远处转移率、III/IV级晚期毒性和小肠梗阻率无显著差异。

要点

  • 放化疗组5年无进展生存80.2% vs 单纯放疗组74.5%,差异显著。
  • 放化疗组5年癌症特异性生存86.1% vs 单纯放疗组79.0%,差异显著。
  • 放化疗组III/IV级急性毒性发生率更高,但晚期毒性和小肠梗阻率无显著差异。

核心结论

  • 对于FIGO I-III期伴危险因素的子宫内膜癌患者,术后辅助放化疗较单纯放疗可显著改善无进展生存和癌症特异性生存。
  • 除急性毒性增加外,放化疗在高危子宫内膜癌患者中耐受性良好。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、EMBASE、Cochrane Library、Web of Science和ClinicalTrials.gov五个数据库并辅以手工检索,纳入2017年12月9日前发表的前瞻性随机对照试验。
  • 共纳入6项比较术后放化疗与单纯放疗的高危子宫内膜癌随机对照试验,涉及2105例患者(放化疗组n=1064,放疗组n=1041)。

主要发现

  • 总生存无统计学显著差异(n=2105,RR=1.02,95%CI 0.98-1.06,P=0.40)。
  • 局部复发率无显著差异(n=690,RR=0.48,95%CI 0.19-1.18,P=0.11);远处转移率无显著差异(n=1445,RR=0.94,95%CI 0.72-1.23,P=0.67)。
  • 放化疗显著延长5年无进展生存(80.2% vs 74.5%,提高5.7个百分点,RR=1.08,P=0.005)和5年癌症特异性生存(86.1% vs 79.0%,提高7.1个百分点,RR=1.09,P=0.03)。
  • 放化疗组III/IV级急性毒性发生率更高(P<0.00001);III/IV级晚期毒性和小肠梗阻率两组无显著差异。

临床怎么用

  • 作者认为,对于FIGO I-III期伴危险因素的子宫内膜癌患者,术后辅助放化疗较单纯放疗可显著改善无进展生存和癌症特异性生存。
  • 作者指出,除急性毒性增加外,放化疗在高危子宫内膜癌患者中耐受性良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefits of adjuvant chemoradiotherapy (CRT) for high-risk endometrial cancer (HREC) in International Federation of Gynecology and Obstetrics (FIGO) stages I-III remain controversial. A systematic review and meta-analysis was conducted to evaluate the clinical effectiveness and safety of postoperative CRT over radiotherapy (RT) alone, exclusively for patients with HREC for the following key endpoints: overall survival (OS), progression-free survival (PFS), the local recurrence rate, the distant metastasis rate, cancer-specific survival (CSS), grade III/IV acute and late toxicities, and the small bowel obstruction rate. METHODS: Five databases, namely, PubMed, EMBASE, Cochrane Library, Web of Science and ClinicalTrials.gov, were systematically explored and supplemented by manual searching to identify relevant studies published before Dec 9, 2017. Only prospective randomized controlled trials (RCTs) conducted for HREC comparing CRT and RT alone after surgery were included. All statistical analyses were performed using RevMan Version 5.3 software. RESULTS: Six eligible trials involving 2105 patients were identified for the final meta-analysis (CRT: n = 1064; RT: n = 1041). No statistically significant differences were evident between the CRT and RT groups regarding OS (n = 2105, RR = 1.02, 95% CI 0.98-1.06, P = 0.40). Additionally, no differences were apparent in terms of the local recurrence rate (n = 690, RR = 0.48, 95% CI 0.19-1.18, P = 0.11) or distant metastasis rate (n = 1445, RR = 0.94, 95% CI 0.72-1.23, P = 0.67). However, CRT significantly prolonged overall five-year PFS (80.2% vs. 74.5%, +5.7%; RR = 1.08, P = 0.005) and five-year CSS (86.1% vs. 79.0%, +7.1%; RR = 1.09, P = 0.03). A higher incidence of grade III/IV toxicities (P < 0.00001) was evident with CRT, while grade III/IV late toxicities and the small bowel obstruction rate were not significantly different between the two groups. CONCLUSIONS: For patients with endometrial cancers with stage I-III risk factors, adjuvant CRT can significantly improve PFS and CSS compared with RT. With the exception of increased acute toxicities, CRT is well accepted and tolerated in HREC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Yi L, Zhang H, Zou J, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol. 2018. PMID: 29530332. doi:10.1016/j.ygyno.2018.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。